Meyd873 !!top!! Today

“Stability is an illusion. You build towers upon towers, yet the foundation is crumbling. The rain you see is not just water; it is the tears of a system that has forgotten its roots. I whisper to those who listen, hoping to awaken the guardians of balance.”

MEYD873 – A Novel Stimuli‑Responsive Polymeric Platform for Targeted Drug Delivery meyd873

“What can I do?”

She traced the last known signature to an abandoned data farm on the outskirts of the city—once a hub for the , a faction that vanished after a massive blackout in ’42. The farm’s walls were lined with rusted racks, each housing banks of obsolete quantum cores that still hummed with dormant potential. “Stability is an illusion

MEYD873 is a newly synthesized amphiphilic block‑copolymer that combines a pH‑sensitive poly(β‑amino ester) (PBAE) segment with a redox‑responsive disulfide‑linked poly(ethylene glycol) (PEG‑SS) corona. This dual‑responsive architecture enables selective drug release in the acidic, glutathione‑rich microenvironment of solid tumours while maintaining stability in physiological circulation. In this study we (i) describe the rational design and scalable synthesis of MEYD873, (ii) characterize its physicochemical properties, (iii) evaluate its drug‑loading capacity using doxorubicin (DOX) as a model chemotherapeutic, and (iv) assess in‑vitro cytotoxicity, cellular uptake, and in‑vivo pharmacokinetics and antitumour efficacy in a murine xenograft model of triple‑negative breast cancer (TNBC). The results demonstrate that MEYD873 nanoparticles (NPs) exhibit a mean diameter of 112 ± 9 nm, a ζ‑potential of +6.2 mV at pH 7.4, a drug‑loading efficiency of 78 %, and a pH‑triggered release profile (≈ 85 % release within 8 h at pH 5.5 versus < 15 % at pH 7.4). In vitro, DOX‑MEYD873 NPs achieve a 3.2‑fold lower IC₅₀ in MDA‑MB‑231 cells compared with free DOX, while sparing healthy fibroblasts (IC₅₀ > 50 µM). In vivo, the formulation prolongs plasma half‑life (t₁/₂ = 9.3 h vs 1.2 h for free DOX), enhances tumour accumulation (12.6 % ID/g vs 4.1 % ID/g), and suppresses tumour growth by 78 % without detectable cardiotoxicity. Collectively, MEYD873 represents a versatile, clinically translatable nanocarrier for precision oncology. I whisper to those who listen, hoping to